海南海药(000566) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 130 million yuan and 170 million yuan for the first half of 2024, compared to a profit of 9.5461 million yuan in the same period last year[3]. - The expected operating revenue for the period is between 600 million yuan and 850 million yuan, down from 959.5746 million yuan year-on-year[3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 80 million yuan to 120 million yuan, compared to a loss of 91.5488 million yuan in the previous year[3]. - Basic earnings per share are projected to be a loss of between 0.1002 yuan and 0.131 yuan, compared to earnings of 0.0074 yuan per share in the previous year[3]. Impairment and Investment Income - The company anticipates an increase in credit impairment losses, estimated at approximately 27 million yuan, compared to a gain of 70 million yuan in the same period last year, reflecting a rise of about 96 million yuan[5]. - Investment income is expected to decrease to approximately -58 million yuan, down from -12 million yuan year-on-year, a decline of about 45 million yuan[5]. Financial Reporting - The financial data in this earnings forecast has not been audited by registered accountants[4]. - The company will provide detailed financial data in its 2024 semi-annual report[6].